Protagonist Stock 120%, Fund Outlook and Exit Signals
A hedge fund's sizable exit from Protagonist Therapeutics highlights how insiders and funds shape biotech stock moves...
Analyze how volatility differs between index funds and bonds in retirement, and craft a plan that moderates swings while pursuing growth.
23,614 articlesA hedge fund's sizable exit from Protagonist Therapeutics highlights how insiders and funds shape biotech stock moves...
Can a $5,000 investment unlock big potential in quantum computing stocks? This guide breaks down the landscape, insid...
A major fund trimmed its stake in a biotech ahead of a June FDA milestone. This article explains what that means for ...
As GLP-1 therapies reshape obesity treatment, investors eye the best weight loss drug stock bets for 2026. This guide...
Is SpaceX heading to the stock market? This article breaks down the IPO question with insights inspired by Jim Cramer...
A potential agreement with Iran could unlock sanctions relief, release frozen assets, and reopen Gulf shipping. Negot...
SpaceX going public soon would shake investor interest in the space economy. This guide shows how to position yoursel...
Investors eye the long end of the curve as Kevin Warsh's QT stance shifts income dynamics. Forget utility dividends. ...
SpaceX's S-1 filing exposes Bitcoin exposure and a broader digital-asset playbook, signaling a new price benchmark fo...
May delivered a sharp reversal for Bitcoin ETFs, with the biggest weekly outflows since January as risk-off trading s...
A Hong Kong based fund recently exited its stake in a leading China logistics platform for about $194 million. This a...
The Defense Department expanded its 1260H roster to label Alibaba and Baidu as aiding the PLA, with BYD also targeted...